Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid for prognosis in spontaneous intracerebral hemorrhage
IRCT20241016063386N2Phase 3Recruiting
- Sponsor
- Urmia University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tranexamic acid in intracerebral hemorrhage (ICH) and intracerebral hematoma (ICH) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoint: Intracerebral hemorrhage volume. Started Feb 2026; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
intracerebral hemorrhage (ICH)intracerebral hematoma (ICH)
Beyond the preview
Go deeper on IRCT20241016063386N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241016063386N2.